Eckburg Paul
SEC CIK 1914512 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | Chief Medical Off | 51.4K | — | — | 2 | 2024-03-15 | 2024-03-15 |
Most active insiders at ANTX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Readnour Robin Shane | Dir | — | $316.7K |
| 2 | Eizen Joshua M | See Remarks | — | $52.9K |
| 3 | FitzPatrick Margaret M | Dir | $11.6K | — |
| 4 | Chanda Sanjay | Chief Development Off | — | $9,311 |
| 5 | Day Lucy | CFO | — | $8,862 |
| 6 | Prior Stephen David | Chief Strategy Off | — | $7,363 |
| 7 | Williams Sarah Joanne | Principal Accounting Off | — | $3,025 |
| 8 | Trenor Cameron C. III | Chief Medical Off | — | — |
| 9 | Marks Gilbert Lynn | Dir | — | — |
| 10 | Martin Patricia A. | Dir | — | — |
Eckburg Paul made no open-market trades at ANTX in the last 12 months.
Transactions 2
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2024-03-29 | 2024-03-15 | ANTX | AN2 Therapeutics, Inc. | Eckburg Paul | Chief Medical Off | A - Grant | $0.00 | +30.0K | 51.4K | +140% | $0 |
| D | 2024-03-18 | 2024-03-15 | ANTX | AN2 Therapeutics, Inc. | Eckburg Paul | Chief Medical Off | A - Grant | $0.00 | +30.0K | 51.4K | +140% | $0 |
Purchase Sale Sale after option exercise All abbreviations